DataString Consulting Company Logo
DataString Consulting Company Logo
Lotilaner Market
Home»Recent Reports»Lotilaner Market

Lotilaner Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802314, Published - May 2025

Segmented in Product Application (Flea & Tick Control, Animal Healthcare, Veterinary Pharma), User Types (Veterinarians, Pet owners, Farmers), Dosage Type, Sales Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Lotilaner Market Outlook

The market, for Lotilaner was estimated at $432.2 million in 2024; and it is anticipated to increase to $659.6 million by 2030 with projections indicating a growth to around $938.2 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.3% over the forecast period. Lotilaners enduring importance in its market is supported by a variety of essential factors driving its success and popularity among customers due to its strong performance and versatile applications across different areas of use. Its inherent qualities align with the changing market trends and evolving customer requirements which have contributed to its increasing significance over time. In summary Lotilaners role continues to grow promising contributions, to theindustry'sdevelopment and vitality. Moreover its continued importance showcases the adaptability of Lotilaner and its deep ability to innovate in response, to trends.


Lotilaner is known for its accuracy and dependability in the health industry when it comes to preventing and treating fleas and ticks in dogs – making it a top choice due to its effectiveness, in combating these common issues.


Market Size Forecast & Key Insights

2019
$432M2024
2029
$874M2034

Absolute Growth Opportunity = $442M

The Lotilaner market is projected to grow from $432.2 million in 2024 to $874 million in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Flea & Tick Control, Veterinary Pharmaceuticals and Animal Healthcare.

The Lotilaner market is set to add $442 million between 2024 and 2034, with manufacturer targeting Pet owners & Farmers User Types projected to gain a larger market share.

With Surge in pet ownership, and Growing awareness of zoonotic diseases, Lotilaner market to expand 102% between 2024 and 2034.

Opportunities in the Lotilaner Market

Emergence of Pet-Centric Consumerism

The growing emphasis on pet focused consumer behavior presents an opportunity for Lotilaner products, in the market landscape.

Veterinary Medicine Advancements and Strategic Partnerships in Pharma

The development of animal healthcare and emphasis on advancements in medicine offer a promising opportunity for Lotilaner, an antiparasitic medication utilized for managing fleas and ticks in canines to make substantial progress in emerging markets where pet health is becoming increasingly crucial due to the alignment of a market gap and technological progress, in veterinary medicine.

Collaborating strategically with companies in the pharmaceutical industry could significantly boost the progress of Lotilaner pushing its presence and utilization into new regions effectively by teamworking with reputable firms thus fostering innovation and opening up opportunities, for varied uses and applications of Lotilaner.

Growth Opportunities in North America and Europe

Europe Outlook

Europe has a pharmaceutical industry and a high rate of pet adoptions which makes it a vibrant market for Lotilaner products against flea and tick infestations as there is an increasing demand for effective treatments like Lotilaner due to tough competition among leading market players resulting in a variety of Lotilaner products available in the market that contributes to its growth potential in the region boosted by factors such as rising awareness about pet health care and disposable income along with an increase, in the number of veterinary clinics. In Europe though some factors that could hinder the market are the saturated developed markets and the strict regulations imposed by the European Medicines Agency.

North America Outlook

North America is known as a center for producing and using Lotilaner due to its advanced veterinary healthcare systems and growing emphasis on pet well being. The United States is home to pharmaceutical companies that create a high demand for Lotilaner because of the widespread problem of parasites in the region. Furthermore there are players in the market who offer innovative forms of Lotilaner. However stringent regulations and approval procedures in North America could pose obstacles, to the sectors expansion. The adoption of technology for treating parasites is a key factor driving the anticipated growth, in market performance in this region.

North America Outlook

North America is known as a center for producing and using Lotilaner due to its advanced veterinary healthcare systems and growing emphasis on pet well being. The United States is home to pharmaceutical companies that create a high demand for Lotilaner because of the widespread problem of parasites in the region. Furthermore there are players in the market who offer innovative forms of Lotilaner. However stringent regulations and approval procedures in North America could pose obstacles, to the sectors expansion. The adoption of technology for treating parasites is a key factor driving the anticipated growth, in market performance in this region.

Europe Outlook

Europe has a pharmaceutical industry and a high rate of pet adoptions which makes it a vibrant market for Lotilaner products against flea and tick infestations as there is an increasing demand for effective treatments like Lotilaner due to tough competition among leading market players resulting in a variety of Lotilaner products available in the market that contributes to its growth potential in the region boosted by factors such as rising awareness about pet health care and disposable income along with an increase, in the number of veterinary clinics. In Europe though some factors that could hinder the market are the saturated developed markets and the strict regulations imposed by the European Medicines Agency.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, UK, Canada, Australia are expected to grow at 4.7% to 7.0% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 8.4% to 10.1% CAGR

Market Analysis Chart

The demand for Lotilaneran ingredient in veterinary medicine is on the rise due to factors like the increasing prevalence of flea and tick related diseases among pets that require more potent treatments such as Lotilaner for long lasting protection, against these parasites.

Recent Developments and Technological Advancement

November 2024

Zoetis introduced an improved version of their Lotilaner based product for dogs. This upgraded product offers treatment and longer protection, against fleas and ticks.

September 2024

Boehringer Ingelheim has broadened its range of Lotilaner products by combining them with heartworm prevention medicine. This move represents a change in the approach, to managing parasites.

July 2024

Elanco Animal Health unveiled a groundbreaking research study demonstrating the increased effectiveness of their Lotilaner product named Seresto, in managing tick infestations.

Lotilaner is a of ectoparasiticide that has made great strides in the field of pet healthcare industry. It works well in helping companion animals fight off parasites, like fleas and ticks by offering quick and long lasting relief. This marks an advancement in the range of treatments now offered in this particular sector.

Impact of Industry Transitions on the Lotilaner Market

As a core segment of the Pharmaceutical industry, the Lotilaner market develops in line with broader industry shifts. Over recent years, transitions such as Pioneering Shift Towards Environmentally Friendly Parasiticides and Advancements in Parasiticide Delivery Methods have redefined priorities across the Pharmaceutical sector, influencing how the Lotilaner market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Pioneering Shift Towards Environmentally Friendly Parasiticides:

The parasiticide industry is experiencing a shift towards eco friendly options due to the growing demand for sustainable alternatives. Lotilaner stands out as a parasiticide that is highly effective in treating ticks and fleas, in pets and is driving this change. Known for its performance and environmentally friendly nature compared to conventional parasiticides Lotilaners use of the revolutionary isoxazoline compound ensures both effectiveness and minimal harm to the environment. Lotilaners commitment to awareness is reshaping related sectors such, as veterinary medicine and animal care by inspiring industry participants to develop and implement environmentally friendly parasite treatments.

2

Advancements in Parasiticide Delivery Methods:

Amid the growing demand for convenient and efficient administration techniques in the field of parasitic control products there is a push, towards exploring and creating new delivery approaches. Lotilaner, typically given to animals orally is leading this shift.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Lotilaner market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Surge in Pet Ownership, and Technological Advancements in Veterinary Medicine

The growing trend of owning pets globally has also led to a market, for Lotilaner as it effectively safeguards dogs and cats against fleas and ticks.
The progress in medicine and pharmaceutical industry has also revolutionized the care of pets with the introduction of innovative medications, like Lotilaner which offer long lasting effectiveness and quick results.
The increasing knowledge among people regarding diseases is also also driving the need for Lotilaner to rise in demand significantly. As an efficient ectoparasiticide product it plays a pivotal role in stopping the transmission of illnesses such as Lyme disease and other tick borne diseases, in animals and humans alike.

Restraint: Regulatory Challenges

Health organizations around the globe have established regulations that could pose regulatory hurdles for the Lotilaner market in the future. Manufacturers are obligated to conduct comprehensive product testing to meet these standards before receiving approval for distribution. These regulations might delay the products launch. Have implications, on the demand and market trends in the long run.

Challenge: Market Competition

The Lotilaner market is up against competition from other antiparasitic treatments that have been around for a while and are more widely known and trusted by consumers than newer options like Lotilaner are likely to be able to break into the market and make a strong impact on the existing customer base due, to these factors of competition and higher pricing that may hinder its growth and adoption within the market as a whole.

Supply Chain Landscape

Raw Material Suppliers

Chemieliva Pharmaceutical

Alfa Chemistry

Primary Producers

Elanco

Ariel Scientific

Secondary Manufacturers
Zhejiang Hisun Pharmaceuticals / CordenPharma
End User
Veterinary practice / Pet owners
Raw Material Suppliers

Chemieliva Pharmaceutical

Alfa Chemistry

Primary Producers

Elanco

Ariel Scientific

Secondary Manufacturers

Zhejiang Hisun Pharmaceuticals

CordenPharma

End User

Veterinary practice

Pet owners

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Veterinary Flea and Tick Control
Veterinary Pharmaceuticals
Elanco Animal Health Incorporated
Formulated Lotilaner into flavored chewable tablet for effective treatment and control of fleas and ticks in dogs and cats, marketed under the brand name Credelio.
Parasite Resistance Research
Biotech Research
Sequoia Sciences, Inc.
Applying Lotilaner's efficacy against ectoparasites to study its potential in developing new solutions for combating resistance in prevalent parasites.
Agricultural Pest Management
Agrotech
Syngenta Group
Experimenting with Lotilaner for its potential as an insecticide in crop protection, due to its proven potency against certain insect species.
Wildlife Protection
Conservation & Wildlife Management
Wildlife Conservation Society (WCS)
Exploring Lotilaner's use in protection strategies against tick-borne diseases among threatened wildlife populations.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Lotilaner market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Lotilaner in Animal Healthcare and Veterinary Pharmaceuticals and Flea & Tick Control

Animal Healthcare and Veterinary Pharmaceuticals

In the field of animal health care focusing on pets such as dogs and cats; lotilaner plays a vital role by providing essential flea and tick protection through products like lotilaner spot on and oral tablets used by veterinarians. These products are praised for their safety and ease of use which has established companies like Zoetis and Merck Animal Health as leaders, in this field.



Lotilaner also finds use in the veterinary pharmaceutical sector where it is known for its effectiveness against parasitic infestations in dogs notably through products like Lotilaner tablets that are valued for their extended efficacy and ability to prevent serious health concerns, in pets.

Flea & Tick Control

Lotilaner is a of insecticide and acaricide from the isoxazoline class that is mainly used for treating fleas and ticks in a manner due to its effectiveness and quick results with long lasting effects. One significant feature of chewable tablets is their rapid action in getting rid of fleas and ticks on pets shortly after being administered. Making them a popular choice, among pet owners and veterinarians alike. Elanco and other companies utilize lotilaner in products, like Credelio to offer dogs and cats protection from fleas and ticks for a month.

Lotilaner vs. Substitutes:
Performance and Positioning Analysis

Lotilaner, a veterinary ectoparasiticide, boasts superior effectiveness in flea and tick prevention over alternatives like Fipronil, with rapid onset action. Its unique market positioning is underscored by its potential to revolutionize the pet health sector

Lotilaner
  • Fluralaner /
  • Sarolaner /
  • Afoxolaner
    High efficacy in controlling fleas and ticks, Swift onset of action with long-lasting effects
    More research needed for potential side effects, Comparatively high cost
    Effective on a wide range of parasites, prolonged efficacy
    Potential side effects, requires regular administration

Lotilaner vs. Substitutes:
Performance and Positioning Analysis

Lotilaner

  • High efficacy in controlling fleas and ticks, Swift onset of action with long-lasting effects
  • More research needed for potential side effects, Comparatively high cost

Fluralaner / Sarolaner / Afoxolaner

  • Effective on a wide range of parasites, prolonged efficacy
  • Potential side effects, requires regular administration

Lotilaner, a veterinary ectoparasiticide, boasts superior effectiveness in flea and tick prevention over alternatives like Fipronil, with rapid onset action. Its unique market positioning is underscored by its potential to revolutionize the pet health sector

Loading...

Research Methodology

This market research methodology defines the Lotilaner market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Lotilaner across Flea & Tick Control, Animal Healthcare, and Veterinary Pharma Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, and Merck & Co. Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Primary Producers, and Secondary Manufacturers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Lotilaner segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Chemieliva Pharmaceutical, Alfa Chemistry), Primary Producers (Elanco, Ariel Scientific), and Secondary Manufacturers. Our parallel substitute analysis examines Fluralaner, Sarolaner, and Afoxolaner, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, and Merck & Co. Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Lotilaner market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Lotilaner Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 463 million
Revenue Forecast in 2034USD 874 million
Growth RateCAGR of 7.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024432 million
Growth OpportunityUSD 442 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024432 million USD
Market Size 2027533 million USD
Market Size 2029614 million USD
Market Size 2030659 million USD
Market Size 2034874 million USD
Market Size 2035938 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredProduct Application, User Types, Dosage Type, Sales Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledElanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Merck & Co. Inc., Zoetis Inc., Virbac, Perrigo Company plc, Heska Corp, Ceva Sante Animale, Vetoquinol SA, Dechra Pharmaceuticals PLC, Chanelle Pharma and N-Vet AB.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Lotilaner Market Size, Opportunities & Strategic Insights, by Product Application

4.1Flea & Tick Control
4.2Animal Healthcare
4.3Veterinary Pharma
Chapter 5

Lotilaner Market Size, Opportunities & Strategic Insights, by User Types

5.1Veterinarians
5.2Pet owners
5.3Farmers
Chapter 6

Lotilaner Market Size, Opportunities & Strategic Insights, by Dosage Type

6.1Chewable Tablets
6.2Topical Solution
Chapter 7

Lotilaner Market Size, Opportunities & Strategic Insights, by Sales Channel

7.1Pharmaceutical Retail
7.2Veterinary Clinics
7.3Online Stores
Chapter 8

Lotilaner Market, by Region

8.1North America Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Lotilaner Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Elanco Animal Health Incorporated
9.2.2Boehringer Ingelheim International GmbH
9.2.3Merck & Co. Inc.
9.2.4Zoetis Inc.
9.2.5Virbac
9.2.6Perrigo Company plc
9.2.7Heska Corp
9.2.8Ceva Sante Animale
9.2.9Vetoquinol SA
9.2.10Dechra Pharmaceuticals PLC
9.2.11Chanelle Pharma
9.2.12N-Vet AB.